Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

51 52 Next >

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst ↗

April 01, 2024

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.

Via Benzinga

10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗

March 29, 2024

Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...

Via Talk Markets

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why ↗

March 28, 2024

Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered...

Via Benzinga

Analyzing NASDAQ:GILD's Dividend Potential. ↗

March 26, 2024

Is GILEAD SCIENCES INC (NASDAQ:GILD) a Good Fit for Dividend Investing?

Via Chartmill

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today ↗

March 11, 2024

Via Benzinga

Balancing Dividends and Fundamentals: The Case of NASDAQ:GILD. ↗

March 05, 2024

Exploring GILEAD SCIENCES INC (NASDAQ:GILD)'s dividend characteristics.

Via Chartmill

$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today ↗

February 23, 2024

Via Benzinga

Why Is Xilio Therapeutics (XLO) Stock up 168% Today? ↗

March 28, 2024

Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead.

Via InvestorPlace

7 Value Stocks to Buy at a 52-Week Low in March ↗

March 28, 2024

These seven value stocks to buy all trade at low valuations, and have the potential to make big recoveries.

Via InvestorPlace

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 27, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

2 Top Dividend Stocks to Buy Hand Over Fist ↗

March 17, 2024

Every company faces headwinds eventually. The top ones know how to bounce back.

Via The Motley Fool

10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? ↗

March 16, 2024

Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...

Via Talk Markets

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗

March 15, 2024

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...

Via Benzinga

3 Dividend Stocks to Buy Hand Over Fist in March ↗

March 10, 2024

Income investors might want to load up on these great dividend stocks.

Via The Motley Fool

The AI Race Gets Litigious ↗

March 09, 2024

We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗

March 08, 2024

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...

Via Benzinga

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy ↗

March 06, 2024

Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed.

Via Benzinga

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗

March 06, 2024

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...

Via Benzinga

Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound ↗

March 04, 2024

While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.

Via InvestorPlace

Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges ↗

March 04, 2024

The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.

Via Benzinga

Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership ↗

February 24, 2024

Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...

Via Talk Markets

3 Dividend Stocks That Are No-Brainer Buys Right Now ↗

February 24, 2024

These stocks check off multiple boxes for investors.

Via The Motley Fool

History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20% ↗

February 24, 2024

This biotech stock could be poised for a nice rebound if analysts are right.

Via The Motley Fool

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗

February 22, 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

Via InvestorPlace

Stock Alert: 3 Market Giants on the Brink of Monumental Rallies ↗

February 20, 2024

These are the stocks to buy to unlock the secrets of market giants in various industries for monumental growth and returns.

Via InvestorPlace

From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024 ↗

February 19, 2024

Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.

Via InvestorPlace

Why Is Gilead Sciences Stock Trading Lower Today? ↗

February 16, 2024

Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials.

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gilead Sciences (NQ:GILD)

Headline News about Gilead Sciences

Starting at $3.75/week.

Subscribe Today